Free Trial
NASDAQ:SNTI

Senti Biosciences (SNTI) Stock Price, News & Analysis

Senti Biosciences logo
$1.95 -0.06 (-2.99%)
Closing price 04:00 PM Eastern
Extended Trading
$1.99 +0.04 (+2.05%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Senti Biosciences Stock (NASDAQ:SNTI)

Key Stats

Today's Range
$1.93
$2.08
50-Day Range
$1.88
$3.84
52-Week Range
$1.52
$16.94
Volume
168,792 shs
Average Volume
685,991 shs
Market Capitalization
$50.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Buy

Company Overview

Senti Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

SNTI MarketRank™: 

Senti Biosciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 620th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Senti Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Senti Biosciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Senti Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Senti Biosciences are expected to grow in the coming year, from ($14.54) to ($1.88) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Senti Biosciences is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Senti Biosciences is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Senti Biosciences has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Senti Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    7.66% of the float of Senti Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Senti Biosciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Senti Biosciences has recently increased by 114.96%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Senti Biosciences does not currently pay a dividend.

  • Dividend Growth

    Senti Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.66% of the float of Senti Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Senti Biosciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Senti Biosciences has recently increased by 114.96%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Senti Biosciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Senti Biosciences this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for SNTI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Senti Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Senti Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.12% of the stock of Senti Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 25.73% of the stock of Senti Biosciences is held by institutions.

  • Read more about Senti Biosciences' insider trading history.
Receive SNTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SNTI Stock News Headlines

Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
See More Headlines

SNTI Stock Analysis - Frequently Asked Questions

Senti Biosciences' stock was trading at $3.51 at the start of the year. Since then, SNTI stock has decreased by 44.4% and is now trading at $1.95.

Senti Biosciences, Inc. (NASDAQ:SNTI) issued its quarterly earnings results on Tuesday, May, 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by $0.85. The company earned $1.30 million during the quarter, compared to analyst estimates of $1.30 million.

Senti Biosciences shares reverse split on the morning of Thursday, July 18th 2024.The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Senti Biosciences investors own include NVIDIA (NVDA), PayPal (PYPL), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Coinbase Global (COIN) and SoFi Technologies (SOFI).

Company Calendar

Last Earnings
5/06/2025
Today
7/18/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SNTI
CIK
1854270
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$5.00
Potential Upside/Downside
+331.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($10.84)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$52.79 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-177.24%
Return on Assets
-67.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.22
Quick Ratio
4.22

Sales & Book Value

Annual Sales
$2.56 million
Price / Sales
20.07
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.31 per share
Price / Book
0.37

Miscellaneous

Outstanding Shares
26,080,000
Free Float
25,267,000
Market Cap
$51.38 million
Optionable
Not Optionable
Beta
2.09
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:SNTI) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners